

London, United Kingdom – 29 July 2026 - Anastasis Biotec Ltd (ABL), a preclinical stage biotech oncology company, developing proprietary first-in-class therapies to control gene expression by the selective inhibition or modulation of transcription factors in the cell's nucleus, is pleased to announce that on 8 July 2026, the European Patent Office (EPO) officially published and granted the patent titled Peptide Conjugates, patent publication number: EP3673067B1.

The patent full legal status, claims, and downloadable document files can be viewed directly through Espacenet or the European Patent Registry websites.

The newly granted patent has a term of 20 years from August 2018 and expected to expire in August 2038.

It has been a lengthy, laborious and expensive process but one that has further strengthened and expanded ABL's intellectual property portfolio. Europe offers significant opportunities for British life sciences companies, including access to a large market, investors, and partners with expertise in oncology and other therapeutic areas.

Forward-Looking Statement

This document contains forward-looking in accordance with UK practice. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and the reader should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, financing, the development of the S4, AB1, products and the ANTP platform and their commercialization by Anastasis Biotec Limited.

For more information, please contact:

Prof Agamemnon Epenetos PhD , FRCP
Chairman and CEO

agamemnon@anastasisbiotec.com

+44 7785 115 010